CTIS2024-511628-16-00进行中（未招募）1 期
Randomized adaptive assessment of post COVID syndrometreatments (RAPID) Reducing Inflammatory Activity in Patients with post COVID Syndrome(REVIVE) - 2.0
Goethe University Frankfurt0 个研究点目标入组 376 人开始时间: 2024年3月18日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 376
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Male or female patients =18 years of age, Use of a highly effective method of contraception correctly and consistently, as applicable, during trial treatment and for 28 days after the final dose (applicable to individuals of childbearing potential and participating men whose partners may become pregnant), Female patients of childbearing potential, must have a negative pregnancy test (at Screening-V1 (blood test; see Tab. 1) and before the first IMP intake (Day 1 blood or urine test) AND agreement of not to attempt to become pregnant AND agreement of not to donate ova AND usage of highly effective forms of birth control (as defined by Recommendations related to contraception and pregnancy testing in clinical trials- Heads of Medicines Agencies (HMA); see 20.1), Male patients must agree not to father a child or to donate sperm starting at Screening-V1, throughout the clinical study, and for 30 days after the last intake of the IMP. Male patients must also: a.abstain from sexual intercourse with a female partner (acceptable only if it is the patient’s usual form of birth control/lifestyle choice), or b.use adequate barrier contraception during treatment with the IMP and until at least 30 days after the last intake of the IMP, and c.if they have a female partner of childbearing potential, the partner should use a highly effective contraceptive method as outlined above d.if they have a pregnant partner, they must use condoms while taking the IMP to avoid exposure of the fetus to the IMP., Symptoms consistent with PCS that began within 4 weeks of the index infection and persisted for >12 weeks. The identified symptoms of PCS cannot be attributed to other intervening diagnoses or medications and did not exist prior to the acute COVID preceding PCS., Moderate to severe overall disability, defined as a Bell Scale of 20-60, =2 of the following post-COVID symptoms, defined as: a. fatigue, defined as an FSS score =36 b.cognitive impairment, defined as a MoCA score between 10-25.c. shortness of breath, defined as a mMRC =2 d.orthostatic/autonomic dysfunction, defined as the following results in the PST: i.a sustained heart rate increase of =30 bpm within 10 min. of standing or and/or a heart rate reaching >120 bpm within 10 min. of standing and ii. absence of a sustained 20 mmHg decrease in systolic blood pressure within 10 min. of standing, Written informed consent obtained according to international guidelines and local laws, Ability to understand the nature of the trial and the trial related procedures and to comply with them, Ability to provide and use a smartphone, tablet or other device for download and installation of the medical device software used in the trial, Willingness to not connect medical devices used in this trial to any other app that is not defined in this protocol, especially not to Garmin Connect, Willingness to abstain from changes in the type, dosage, and frequency of concomitant medications through Day 84
排除标准
- •Known or planned pregnancy; nursing period, Ongoing SARS-CoV-2 infection or positive test for SARS-CoV-2 within 14 days prior to enrolment, Pre-COVID history of chronic fatigue syndrome or other fatigue syndromes that are due to associated diseases (e.g., cancer, autoimmune diseases), Participation in any other interventional clinical trial within the last 30 days before the start of this trial, Prior use of IMU-838 or a drug prescribed to treat COVID-19 within 30 days, Vaccination for COVID-19 within 28 days prior to enrollment, or other vaccines (influenza, shingles, etc.) within 14 days of enrollment, or planned use of any vaccine until Day 84, Any concomitant disease impairing efficacy endpoint analysis, in the opinion of the investigator, Any use of the following concomitant medications is prohibited during Screening: -Any medication known to significantly increase urinary elimination of uric acid, in particular lesinurad, as well as uricosuric drugs such as probenecid -Treatments for any malignancy, in particular irinotecan, paclitaxel, tretinoin, bosutinib, sorafinib, enasidenib, erlotinib, regorafenib, pazopanib, and nilotinib -Any drug significantly restricting water diuresis, in particular vasopressin and vasopressin analogs -Rosuvastatin at doses of > 10 mg/day -Methotrexate at doses of > 17.5 mg/week, Simultaneous participation in other interventional trials which could interfere with this trial (simultaneous participation in registry and diagnostic trials is allowed), Patient without legal capacity who is unable to understand the nature, significance, and consequences of the trial, Previous participation in this trial, Known or suspected Gilbert syndrome (Morbus Meulengracht), Known or persistent abuse of medication, drugs, or alcohol, Person who is in a relationship of dependence/employment with the sponsor or the investigator, Persons deprived of liberty or placed in an institution by judicial or administrative order, Presence of the following laboratory values at Screening -Platelet count <100,000/mm³ (<100 x 109/L) -Neutrophil count <1,500/mm³ (1.5 x 109/L) -Serum creatinine >1.5 x upper limit of normal (ULN) -Total bilirubin, GOT, GPT, or gGPT >1.5 x ULN -Serum uric acid levels >1.2 x ULN -Indirect (unconjugated) bilirubin >1.2 x ULN, Hypersensitivity to the active substance or to any of the excipients, Severe impairment of liver function (Child Pugh class C), Known history of nephrolithiasis or underlying condition with a strong association of nephrolithiasis, including hereditary hyperoxaluria or hereditary hyperuricemia, History or clinical diagnosis of gout, History of malignancy of any organ system (other than localized basal cell carcinoma of the skin or adequately treated cervical cancer), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases., History of medically significant active, chronic systemic infections (not considering the SARS-CoV-2 infection) within 6 months before Day 1, including, but not limited to tuberculosis, hepatitis B, C or D, and human immunodeficiency virus (HIV), History or presence of serious or acute heart disease such as uncontrolled cardiac dysrhythmia or arrhythmia, uncontrolled angina pectoris, cardiomyopathy, or uncontrolled congestive heart failure (New York Heart Association [NYHA] class 3 or 4), History or presence of any major medical or psychiatric illness which cannot be controlled by medication (e.
研究者
相似试验
招募中
不适用
REturn-to-work And DisAbility Pension afTer COVID-19 virus pandemic. A prospective studyCOVID-19 diseaseNL-OMON23252This study is a collaboration between Zuyderland Medical Center and the Employee Insurance Agency (UWV).2,000
进行中（未招募）
1 期
RANDOMISED EVALUATION OF COVID-19 THERAPY (RECOVERY)COVID-19 (infection with SARS-CoV-2 virus)MedDRA version: 21.1Level: PTClassification code 10035737Term: Pneumonia viralSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.1Level: PTClassification code 10061982Term: Severe acute respiratory syndromeSystem Organ Class: 10021881 - Infections and infestationsEUCTR2020-001113-21-GBniversity of Oxford20,000
尚未招募
Unknown
Prospective Pre-Post Evaluation of Post-Covid and Depression Patients in Psychosomatic RehabilitatioU09.9F32.9Post COVID-19 condition, unspecifiedDepressive episode, unspecifiedDRKS00033791HESCURO Klinik Bad Bocklet100
招募中
1 期
RECOVERYPneumoniaCTIS2023-507441-29-00niversity Of Oxford480
尚未招募
不适用
A cross sectional study to find out the PostCovid complicationsCTRI/2021/12/038493Government Siddha Medical College